CANF - Can-Fite Biopharma L...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $1.88 | Open | $1.84 |
| Volume | 429.6K | Market Cap | 28.33M |
| Yield | Last Dividend |
| Can-Fite (CANF) to Explore RA Drug for C... | 03/06/20 |
| Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus. | |
| Can-Fite BioPharma to Hold Investor Webi... | 11/21/19 |
| PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small mol... | |
| Can-Fite Obtains Patent For Treatment Of... | 11/11/19 |
| Israeli biotechnology company Can-Fite BioPharma Ltd . (NYSE: CANF ) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthri... | |
| Can-Fite Partners, Univo Pharmaceuticals... | 09/10/19 |
| Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) announced Tuesday it has partnered with the medical cannabis company Univo ??? | |
| 10 Biopharmaceutical Companies Trying To... | 08/24/19 |
| Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular ... | |
| The Daily Biotech Pulse: ViiV's Long-Act... | 08/22/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) ... | |
| The Daily Biotech Pulse: Glaukos To Buy ... | 08/08/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) A... | |
| Can-Fite BioPharma Appeals Lawsuit Again... | 07/10/19 |
| Can-Fite BioPharma (NYSE: CANF ) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a sp... | |
| The Week Ahead In Biotech: ASCO Presenta... | 06/01/19 |
| Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price... | |
| The Daily Biotech Pulse: Unity Biotech L... | 05/30/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) C... | |
| Can-Fite BioPharma leads healthcare gain... | 05/20/19 |
| No summary available. | |
| Can-Fite up 5% premarket on namodenonson... | 05/20/19 |
| No summary available. | |
| Can-Fite readies late-stage study of Nam... | 05/06/19 |
| No summary available. | |
| Uber Time (Stocks To Watch Podcast) | 05/05/19 |
| No summary available. | |
| Can-Fite receives $1M upfront payment fr... | 04/15/19 |
| No summary available. | |
| NASH players in the red as EASL announce... | 04/11/19 |
| No summary available. | |
| Can-Fite Biopharma reports FY results | 03/28/19 |
| No summary available. | |
| Can-Fite's namodenoson flunks mid-stage ... | 03/26/19 |
| No summary available. | |
| Biocept and Atossa Genetics among health... | 03/26/19 |
| No summary available. | |
| Conatus flop fails to move NASH players | 03/22/19 |
| No summary available. | |
| Can-Fite Bio up 12% ahead of key data re... | 03/20/19 |
| No summary available. | |
| Conatus up 22% ahead of Emricasan data p... | 03/13/19 |
| No summary available. | |
| Conatus up 22% ahead of Emricasan data p... | 03/13/19 |
| No summary available. | |
| Can-Fite up 10% after expanding its namo... | 02/25/19 |
| No summary available. | |
| Intercept, Gilead, Pfizer And Genfit In ... | 02/05/19 |
| No summary available. | |
| VEDL and OPK among premarket losers | 02/01/19 |
| No summary available. | |
| Can-Fite up 19% premarket on publication... | 01/30/19 |
| No summary available. | |
| Helius Medical: A Failed Clinical Trial,... | 01/29/19 |
| No summary available. | |
| Can-Fite BioPharma (CANF) Presents At Bi... | 01/10/19 |
| No summary available. | |
| Can-Fite BioPharma (CANF) Presents At Bi... | 01/10/19 |
| No summary available. | |
| Date | 2020-06-01 (BMO) | Est. (EPS/Rev.) | ($0.66)/ 1.18M |
| Actual (EPS/Rev.) | $-0.03/ $198.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 84.00 % | Follow |
| Big Data Zhou | Zhou Academy | 81.00 % | Subscribe |
| Swing Trading Cheap Stocks <~ $10 | Michael S. DeVries | 65.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
